Calumet, Inc. enters September with a striking disconnect: the stock has more than doubled year-to-date, yet the Street is still catching up — lifting targets rather than rotating to Sells.
The most important event of the week was fresh analyst action on the very day this note was filed. HC Wainwright raised its price target to $75 from $60, reiterating Buy — a 25% lift in target that now sits well above the current price of $51.52. That followed UBS raising to $47 from $26 on August 25, and Goldman Sachs nudging to $45 from $40 on August 18. The pattern is consistent: every major revision over the past month has been a raise, and none has been accompanied by a rating upgrade to Buy — the firms are chasing the stock higher while keeping cautious ratings. Goldman and UBS remain at Neutral. TD Cowen holds a Hold. The consensus mean target is $53.40, implying less than 4% upside from here at current levels. That compression — between a stock up 9.5% on the week and a consensus that barely has room above it — is the central tension.
The earnings catalyst that reset expectations landed August 7. The stock jumped 8.6% on the day and followed through with a 13.9% gain over the subsequent five sessions — the kind of post-earnings momentum that explains why analysts have been scrambling to reprice. Next results are due November 6, giving the stock a two-month runway before the next fundamental test.
Short positioning tells a comfortable side-story rather than a contested one. Short interest is running at 4.1% of the free float — material enough to note, but far from extreme. The borrow market is loose: availability has climbed to roughly 1,906%, meaning there are nearly twenty shares available to borrow for every one currently shorted. Cost to borrow ticked up 20% on the week to 0.45%, but that remains firmly in "negligible" territory for anyone wanting to initiate a short. The ORTEX short score sits at 42, mid-range and barely moving, consistent with a lack of conviction either way from the short side.
Options positioning adds a mildly constructive note. The put/call ratio has dropped to 0.90, almost 1.75 standard deviations below its 20-day average of 0.96 — the most bullish reading the ratio has hit in weeks. For most of July, the PCR ran above 1.05, signalling persistent demand for downside protection. That overhang has eased materially as the stock gained ground, with call interest now outweighing puts by a wider margin than at any point in recent history. The 52-week PCR low is 0.448, so the current reading is nowhere near the most extreme bullish tilt the market has seen — but the direction of travel is clear.
One structural detail worth monitoring is the ownership register. The Heritage Group holds 16.6% and filed a Schedule 13D/A — activist paperwork — as recently as June 5. Activist-flagged 13D filings carry an intent-to-engage presumption that separates them from purely passive 13G filings, and with Heritage as the anchor holder, any strategic development at Calumet would likely move through that relationship first. Separately, Rajay Bagaria trimmed from 7.0% to 4.6% per an August 14 amendment, dropping below the 5% threshold that typically triggers disclosure obligations — a position worth watching since future reductions may not require further public filings. As always with 13D/G data, stakes are as last disclosed and holders can fall below 5% without another filing.
The conversation to track heading into November is whether the Street's consensus — still weighted toward Neutral despite an unbroken streak of upward revisions — starts shifting to outright Buy ratings, or whether the stock price simply outruns the target upgrades and forces a harder valuation conversation.
See the live data behind this article on ORTEX.
Open CLMT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
